RenovoRx Prices $1.5M Registered Direct Offering
Ticker: RNXT · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, registered-direct-offering, capital-raise
TL;DR
RenovoRx just raised $1.5M via stock sale to fund platform development.
AI Summary
RenovoRx, Inc. announced on April 18, 2024, that it entered into a securities purchase agreement on April 17, 2024, to sell approximately $1.5 million of its common stock and warrants in a registered direct offering. The company expects to close this offering on or about April 22, 2024. The net proceeds will be used for general corporate purposes, including advancing its RenovoCath platform.
Why It Matters
This capital raise provides RenovoRx with funds to continue developing its RenovoCath platform, potentially advancing its therapeutic offerings and market position.
Risk Assessment
Risk Level: medium — The company is raising capital through a stock offering, which can dilute existing shareholders and indicates a need for funding to continue operations and development.
Key Numbers
- $1.5M — Registered Direct Offering Amount (Funds raised for general corporate purposes and platform advancement.)
Key Players & Entities
- RenovoRx, Inc. (company) — Registrant
- April 18, 2024 (date) — Report Date
- April 17, 2024 (date) — Securities Purchase Agreement Date
- $1.5 million (dollar_amount) — Amount of registered direct offering
- April 22, 2024 (date) — Expected Closing Date
- RenovoCath (company) — Platform being advanced
FAQ
What is the purpose of the registered direct offering?
The proceeds from the offering are intended for general corporate purposes, including the advancement of the RenovoCath platform.
When was the securities purchase agreement entered into?
The securities purchase agreement was entered into on April 17, 2024.
What is the expected closing date for the offering?
The offering is expected to close on or about April 22, 2024.
What type of securities are being sold in the offering?
The offering involves the sale of common stock and warrants.
What is the company's principal executive office address?
The registrant's principal executive offices are located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-18 16:15:27
Key Financial Figures
- $2.5 million — he Nasdaq Capital Market, including the $2.5 million minimum stockholders' equity requiremen
Filing Documents
- form8-k.htm (8-K) — 33KB
- ex99-1.htm (EX-99.1) — 15KB
- 0001493152-24-015192.txt ( ) — 218KB
- rnxt-20240418.xsd (EX-101.SCH) — 3KB
- rnxt-20240418_lab.xml (EX-101.LAB) — 33KB
- rnxt-20240418_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: April 18, 2024 By: /s/ Shaun Bagai Name: Shaun R. Bagai Title: Chief Executive Officer